Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Head and neck cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.
- 06 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.